ArticleNeurology and therapy2018

A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia.

David Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.